5h agoBarron'sBULLISH 78Product/PR
Archived explainer. For the current picture see today's RARE page.
Why Is ULTRAGENYX PHARMACEU (RARE) Stock Up Today?
By the Top Tier Newswire AI Desk · September 17, 2026 at 3:57 PM ET · reviewed against 7 wire stories
ULTRAGENYX PHARMACEU (RARE) is up +11.61% in the latest session. Our newswire has captured 7 stories on RARE across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why RARE stock is up today
RARE stock is up 11.61% to $14.38 as of the latest trade, driven by the U.S. Food and Drug Administration's approval of Ultragenyx's FAYUVI™ gene therapy for Sanfilippo syndrome Type A. The approval marks a milestone for the company and offers a first-ever treatment option for this rare pediatric condition. The news has generated strong investor interest, with the stock trading significantly above its 52-week low and showing robust intraday momentum.
What Happened
Ultragenyx announced the FDA's approval of FAYUVI™, a groundbreaking gene therapy for Sanfilippo syndrome Type A. This treatment is the first of its kind and is designed to address the root cause of the disease, potentially halting or slowing the progression of severe neurological decline. The approval follows months of anticipation and is seen as a significant step forward for the company's pipeline. The stock opened with a small gap up and continued to climb throughout the session, reaching an intraday high of $14.55 before settling near that level. Call volume has also been above normal, reflecting directional bullishness.
What The Data Shows
The stock opened at $13.00, a modest 0.9% gap up from the previous close of $12.88. It has since surged to $14.38, with 8.8 million shares traded so far, which is 3.2 times the 3-month average. The stock has moved up 11.61% for the session, a sharp reversal from its recent 8-session trend of falling 8.1% to $13.61. The stock is currently trading near its 52-week high of $39.89 but remains well below that level. On September 17, the stock printed two fresh 52-week lows, highlighting the recent volatility. Additionally, insiders have sold a total of $340K in shares over the past 90 days, with the most recent sale occurring on September 15.
What To Watch
The company has no earnings scheduled in the near term. Investors should continue to monitor the breadth of coverage and analyst sentiment, as well as any further developments related to FAYUVI™ commercialization and its potential impact on the company's financials.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RARE by the numbers
Last: $14.38Session: +11.61%7 sessions: -8.13%Coverage: 7 stories / 6 sourcesAI sentiment: 68/100 (bullish)Mkt cap: $1.3B52w: $12.73 to $39.89
The headlines behind the move
5h agoStockTitanBULLISH 78Product/PR
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A
5h agoSeeking AlphaBULLISH 78Product/PR
Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome
FDA approves Ultragenyx’s Fayuvi, first pediatric gene therapy for Sanfilippo A targeting root cause. Read more here.
5h agoInvesting.com MarketsBULLISH 78Product/PR
Ultragenyx stock surges 10% on FDA approval for gene therapy
Ultragenyx stock surges 10% on FDA approval for gene therapy
6h agoThe FlyBULLISH 73Product/PR
FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A
1d agoStocktwits NewsBEARISH 28General
RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares
RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.
1d agoThe FlyBULLISH 63General
Ultragenyx call volume above normal and directionally bullish
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on RARE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RARE move explainers: 2026-09-17 · 2026-09-04 · 2026-09-03